EGFR and neoplasm: There was no significant difference in pCR rates between 17 patients with PIK3CA mutated vs. 52 patients with PIK3CA wild-type (WT) tumours (47% vs. 46.1%; p = 1.000) or between 8 patients with ERBB family mutated vs. 61 patients with ERBB family WT tumours (62.5% vs. 47.5%; p = 0.477).